Published on
July 9, 2024
- 11:53 GMT
Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36), a Novel Oral Antipsychotic
-Statistically significant benefit demonstrated in primary endpoint of positive subscale of the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) at Week 4- -Dose-response was demonstrated, consistent with higher efficacy in the 40 mg dose- - …
Distribution channels:
Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry
...
